Eli Lilly First to Use Germany’s New Confidential Pricing for Mounjaro

Eli Lilly and Company (NYSE:LLY) is one of the best upside stocks to invest in now. On August 11, Eli Lilly announced its decision to use the confidential reimbursement price option in Germany for its Type 2 diabetes/T2D treatment, Mounjaro (tirzepatide). This marks the first time a company has taken advantage of this option since it was introduced at the beginning of 2025 under the Medical Research Act (Medizinforschungsgesetz, or MFG).

The negotiations for Mounjaro’s T2D reimbursement price between Lilly and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have already been concluded. The introduction of confidential pricing in Germany has been a source of controversy. The country has historically been a champion of price transparency, with discounted reimbursement prices for new therapies being publicly accessible.

Eli Lilly First to Use Germany's New Confidential Pricing for Mounjaro

The new policy was opposed because of the fear that it would lead to a rise in reimbursement costs. However, because of their lobbying, the final version of the MFG included an additional 9% discount on top of the negotiated discount for any company opting for confidential pricing, as well as a requirement to pay back overcharged surcharges and sales tax.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

While we acknowledge the potential of LLY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.